A white "Biointelect" logo is displayed against a dark green/black background.
Search
Contact Us
Home › Company › Executive Strategy Panel

Executive Strategy Panel

Our Biointelect Executive Strategy Panel (ESP) propels our life science consulting to the next level to bring unparalleled value to our clients. The Biointelect ESP brings together a collective of leading sector experts to provide strategic advice on all facets of the Biointelect service offering.

The Biointelect ESP Value

At Biointelect, we believe that healthcare should be accessible to everyone, and we are committed to using our expertise and resources to make that a reality.

The Biointelect ESP is supported by Biointelect’s client service teams working across the life sciences ecosystem to drive new technologies and innovations in the healthcare sector.

The combined expertise of the Biointelect ESP extends across:

  • International health policy
  • Early-stage commercialisation
  • New product commercialisation
  • Market access and reimbursement
  • Government policy and industry partnerships
  • Organisational transformation
  • Board strategic advisory services
  • Regulation of health technologies
Jennifer Herz, Co-founder of Biointelect
Jennifer Herz

Co-founder & Director

Bruce Goodwin

Former Janssen ANZ Managing Director

Franz Pichler

Former Eli Lilly Senior Director, Global Policy and Public Affairs 

Thomas Lönngren

Former European Medicines Agency Executive Director 

Get in Touch

Do you want to learn more about how the insights from Biointelect’s ESP can help bring your innovative life science to market?

Take the next steps in advancing healthcare for all by contacting our team of local Australian and global life science experts today.

Contact Us
Jennifer Herz, Co-founder of Biointelect

Jennifer Herz

Co-founder & Strategic Advisor

Jennifer Herz, GAICD, co-founded Biointelect in 2011, offering end-to-end strategic commercialisation services to the biopharmaceutical sector. She has over 30 years of experience in commercial, business development and scientific affairs within the biopharmaceutical industry across Australia, New Zealand and Europe. 

Early in her career, she played a pivotal role at Sanofi Pasteur, establishing and managing the company as a major provider of vaccines in Australasia. She was also the founding Chair of the Medicines Australia Vaccine Industry Group and has extensive Board experience, serving for publicly listed private and not-for-profit organisations, including Medicines Australia. She then took on a regional policy and market access role where she was engaged in various international industry association working groups, fostering relationships with health authorities, the EU institutions, and the WHO. 

More recently, Jennifer took on Director roles in two NASDAQ-listed US-based biotech company subsidiaries in Australia, became a member of influential committees like the NHMRC’s Health Research Impact Committee, the NSW Innovation and Productivity Council, and the Australian AMR Network’s steering committee.

During her time leading Biointelect, she has overseen more than 450 projects, providing rich and diverse experience in the complexity of life science product development and integrated commercial strategy. This experience includes successful FDA, EMA and TGA approvals, global launches, and product and company failures, providing valuable learning opportunities. 

 Jennifer has an extensive local and international network of industry, policy, scientific and clinical experts across many therapeutic areas and healthcare sectors, along with global experience in multiple new product launches and start-ups at all stages of development. 

Bruce Goodwin

Non-Executive Director & Business Advisor

Bruce Goodwin is currently Strategic Advisor to Omico, a national oncology molecular screening and clinical trials company having recently completed the role of Acting CEO. He is also Non-Executive Director of two patient support organisations and a research start-up focused on novel therapies in mental health.​

He has 37 years of experience in the Global Biopharmaceutical industry having previously been employed by the Janssen Pharmaceutical Companies of Johnson & Johnson. His employment with Janssen included large/multi-country leadership roles resulting in significant commercial success. Prior to that he held senior Commercial (Sales & Marketing) and Finance roles. Bruce also has global licensing & acquisition experience, has led multiple acquisition integrations for Asia-Pacific region, and has established multiple co-promotion partnerships.​

Bruce is a respected Industry Leader with more than a decade of experience at Board level in industry peak bodies in Australia and Japan. This included direct involvement in the negotiation of industry agreements with the Australian Commonwealth Government.​

Dr Franz Pichler

Former Eli Lilly Senior Director, Global Policy and Public Affairs

Franz specialises in international health policy, advocacy, and health system reform relating to the development, assessment, and utilization of innovative medicines and technologies. He combines his technical understanding with policy analysis to develop external affairs strategies and execute such strategies via various engagement approaches including thought leadership in public fora, developing reports, or writing publications. His current work with a broad range of stakeholders provides him with a contemporary understanding of the core policy challenges relating to innovation and the differing perspectives of the various stakeholders involved in commercialising, reviewing, or utilising such technologies. As a result, he can provide coaching, strategic advice, and insights, or direct support to Biointelect clients in relation to external policy engagement across a range of key markets.

Thomas Lonngren

Former European Medicines Agency Executive Director

Thomas Lonngren is a seasoned pharmaceutical executive with a wealth of experience in drug regulation, approval, market access, management, strategy, and leadership. He is best known for his outstanding leadership as the Executive Director of the European Medicines Agency (EMA), where he successfully steered the agency from relative obscurity to global recognition as a world leader in drug regulation during his 10-year tenure from 2001 to 2010.​

Since stepping down from his role at the EMA, Thomas has leveraged his extensive knowledge and experience to provide expert advice to pharmaceutical and Biotech companies worldwide. His focus has been on helping US-based biotech companies located in Boston, Cambridge, New York, and San Francisco navigate the complex landscape of drug development, with a particular emphasis on regulatory and market access considerations.​

Apart from his advisory work, Thomas has also served as a non-executive independent board member in Biotech and MedTech companies for over a decade. This experience has given him a unique perspective on the challenges and opportunities facing the industry, and he has used this knowledge to guide companies towards sustainable growth and success.

Eri Nishiuchi

Strategic Development and Business Effectiveness

Eri Nishiuchi holds a Bachelor of Business degree from the University of Technology Sydney. Her expertise lies in health systems analysis and client relationship management within the healthcare and life sciences sectors. She also has experience working with patient organisations.

Throughout her career, Eri has provided competitive landscape research support to pharmaceutical and biotech clients across the Asia Pacific region, achieving one of the top client retention rates in the region. Her multilingual abilities have been instrumental in fostering strong relationships with diverse stakeholders.

Eri joined Biointelect in 2024 in a strategic development and business effectiveness role, where her focus will be on conducting market analysis and improving business processes.